Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 106, Issue 1, 2008, Pages

  Migliorati, Cesar A ^a   Armonis, Basil N ^b   Nicolatou Galitis, Ourania ^c  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b Oncology 6th IKA Hospital   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IBANDRONIC ACID;

AGED; ARTICLE; BONE NECROSIS; BONE TUMOR; BREAST TUMOR; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; JAW DISEASE; METASTASIS; PATHOLOGY;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; MANDIBULAR DISEASES; OSTEONECROSIS;

EID: 46149108856     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2008.03.005     Document Type: Article

References (26)

1. Hillner B.E., Ingle J.N., Chlebowski R.T., Gralow J., Yee G., Janjan N., et al. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer. J Clin Oncol 21 (2003) 4042-4057
2. Body J.J. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 14 (2006) 408-418
3. Bobba R.S., Beattie K., Parkinson B.B., Kumbhare D., and Adachi J.D. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant disease. Drug Saf 29 (2006) 1133-1152
4. Tripathy D., Body J.J., Diel I., and Bergstrom B. Alleviation of bone pain with oral and intravenous ibandronate in women with metastatic breast cancer. Eur J Cancer 1 Suppl.5 (2003) S136
5. Body J.J., Diel I.J., Bergstrom B., Kreuser E.D., Dornoff W., Gorbunova V.A., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14 (2003) 1399-1405
6. Bondronat intravenous formulation, product information for Europe. http://www.bondronat.com/gear/contents/servlet/staticfilesServlet?type=d ata&communityId=re714004&id=static/attachedfile/re7300002/re7170 0003/AttachedFile_03549.pdf Accessed September 24, 2007
7. Bondronat oral formulation, product information for Europe. http://www.bondronat.com/gear/contents/servlet/staticfilesServlet?type=d ata&communityId=re714004&id=static/attachedfile/re7300002/re7170 0003/AttachedFile_03551.pdf Accessed September 24, 2007
8. Boniva oral/intravenous formulations, prescribing information. http://www.rocheusa.com/products/Boniva/PI.pdf Accessed September 24, 2007
9. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7 (2006) 508-514
10. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
11. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
12. Migliorati C.A., Schubert M.M., Peterson D.E., and Seneda L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive care in cancer. Cancer 104 (2005) 83-93
13. Woo S.-B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
14. Licata A.A. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39 (2005) 668-677
15. Mashiba T., Mori S., Burr D.B., Komatsubara S., Cao Y., Manabe T., et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 23 suppl (2005) 36-42
16. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., and Pak C.Y.C. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (2005) 1294-1301
17. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis.osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
18. Migliorati C.A., Casiglia J., Epstein J., Jacobsen P.L., Siegel M.A., and Woo S.B. Managing the care of patients with bisphosphonate-associated osteonecrosis. An American Academy of Oral Medicine position paper. J Am Dent Assoc 136 (2005) 1658-1668
19. Malden N.J., and Pai A.Y. Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J 203 (2007) 93-97
20. Edwards B.J., Gounder M., McKoy J.M., Raisch D., Farrugia M., Migliorati C., et al. Bisphosphonate use and osteonecrosis of the jaw: pharmacovigilance and reporting of this serious adverse event from the Research on Adverse Drug Events and Reports (RADAR) project. J Clin Oncol 25 18s (2007) June Supplement, Abstract 6519
21. Body J.J., Coleman R., Clezardin P., Ripamonti C., Rizzoli Y., and Aapro M. International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in the elderly. Eur J Cancer 43 (2007) 852-858
22. Strampel W., Emkey R., and Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30 (2007) 755-763
23. Bergner R., Henrich D.M., Hoffmann M., Honecker A., Mikus G., Nauth B., et al. Renal safety and pharmacokinectics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol 47 (2007) 942-950
24. Bobba R.S., Beattie K., Parkinson B., Kumbhare D., and Adachi J.D. Tolerability of different dosing of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 29 (2006) 1133-1152
25. De Cock E., Hutton J., Canney P., Body J.J., Barret-Lee P., Neary M.P., et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther 27 (2005) 1295-1310
26. Boonyapakorn T., Schirmer I., Reichart P.A., Sturm I., and Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol (2008) [epub ahead of press]